Zura Bio Limited
NasdaqCM ZURA
Zura Bio Limited Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2024
Zura Bio Limited Free Cash Flow Per Share is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.
Key data
| Date | Free Cash Flow Per Share | Return on Assets (ROA) | Return on Equity (ROE) | Return on Capital Employed (ROCE) |
|---|
Market news
Loading...
NasdaqCM: ZURA
| CEO | Mr. Robert Lisicki |
| IPO Date | March 21, 2023 |
| Location | United States |
| Headquarters | 4225 Executive Square |
| Employees | 14 |
| Sector | Health Care |
| Industries | |
Description
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email